Unraveling Prostate Cancer Genomics, Pathology, and Magnetic Resonance Imaging Visibility.

[1]  Kathleen E. Houlahan,et al.  Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer. , 2019, European urology.

[2]  A. Evans,et al.  Role of Magnetic Resonance Imaging Targeted Biopsy in Detection of Prostate Cancer Harboring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma , 2018, The Journal of urology.

[3]  A. Rosenkrantz,et al.  Prostate Cancers Detected by Magnetic Resonance Imaging-Targeted Biopsies Have a Higher Percentage of Gleason Pattern 4 Component and Are Less Likely to Be Upgraded in Radical Prostatectomies. , 2018, Archives of pathology & laboratory medicine.

[4]  D. Lu,et al.  Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging. , 2019, European urology.

[5]  Baris Turkbey,et al.  Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. , 2015, JAMA.

[6]  Laurent Lemaitre,et al.  Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients (MRI-FIRST): a prospective, multicentre, paired diagnostic study. , 2019, The Lancet. Oncology.

[7]  David Y. Lu,et al.  Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology. , 2015, European urology.

[8]  M. Parmar,et al.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confi rmatory study , 2018 .

[9]  T. H. van der Kwast,et al.  A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies. , 2017, European urology.